Retension Pharmaceuticals, Inc. has announced a notable stock transaction involving one of its directors, Donald Olds. On October 13, 2026, Olds acquired 5,637 shares of common stock. Additionally, he converted an equal number of Series A Convertible Preferred Stock into common shares. This transaction is significant as it demonstrates the director's commitment to the company and may influence investor confidence.
Background
Retension Pharmaceuticals, Inc. operates in the pharmaceutical preparations industry, classified under SIC code 2834. The company is publicly traded on the Nasdaq under the ticker RTSN. As an emerging growth company, Retension focuses on developing innovative pharmaceutical solutions. Recent filings include several Form 4 submissions, indicating ongoing activity within the company's ownership structure.
What the Filing Says
The filing states, "Olds acquired 5,637 shares of common stock on October 13, 2026." It also notes that the Series A Convertible Preferred Stock was converted into common stock, with the same number of shares involved in the transaction.
Impact
This acquisition may affect investor sentiment towards Retension Pharmaceuticals. As a director, Olds' investment could signal confidence in the company's future prospects. The transaction also highlights the active participation of company leadership in its financial health.
What's Next
The filing does not say what happens next.